ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.
Background: Recurrent high-grade gliomas progressing after surgery and temozolomide plus radiation therapy have traditionally been treated using antiangiogenic drugs as the first-line therapy. Since the phase 3 EORTC 26101 trial showed no significant benefit of administering antiangiogenic drugs, th...
| Publicado en: | Acta Radiologica Vol. 61; no. 3; pp. 404 - 414 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
Sage Publications Inc.
Mar2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Background: Recurrent high-grade gliomas progressing after surgery and temozolomide plus radiation therapy have traditionally been treated using antiangiogenic drugs as the first-line therapy. Since the phase 3 EORTC 26101 trial showed no significant benefit of administering antiangiogenic drugs, the need to identify a biomarker to classify subgroups of potential responders has increased. Purpose: To investigate the feasibility of using apparent diffusion coefficient as a predictor of the response of recurrent high-grade gliomas to bevacizumab or classifier for patients showing better response. Material and Methods: This retrospective study analyzed magnetic resonance images obtained from 39 patients at the time of high-grade glioma progression who were treated using bevacizumab. The apparent diffusion coefficient maps were quantified and modelled as a mixture of Gaussian functions. The correlation of their descriptors and the time to second progression was studied. Log-rank tests were performed to determine the power of these descriptors as the classifiers for patients exhibiting better survival. Results: None of the descriptors showed correlation with time to second progression (r < 0.35) but several of them stratified subgroups showing a better time to second progression passing log-rank tests (P < 0.02). Conclusion: Apparent diffusion coefficient cannot be used to predict the time to second progression of recurrent high-grade gliomas treated with bevacizumab, but it can stratify groups with better time to second progression distributions. |
|---|